Genital itch

ℹ️

Clinical Definition: Genital itch (pruritus genitalis) is a symptom complex characterised by persistent or recurrent itching of the external genitalia and perianal region, arising from infective, inflammatory, or dermatological causes requiring systematic evaluation.

Introduction & Australian Epidemiology

Genital itch is one of the most common presentations to Australian general practice and sexual health clinics, accounting for approximately 3–5% of all dermatology referrals. The condition affects individuals of all ages and sexes, with distinct aetiological profiles across age groups. In Australia, fungal infections (candidiasis, tinea cruris) and contact dermatitis represent the majority of cases in reproductive-age adults, while lichen sclerosus predominates in post-menopausal women and older men. The Australian Institute of Health and Welfare (AIHW) reports sexually transmitted infections including pubic lice and scabies disproportionately affect Aboriginal and Torres Strait Islander (ATSI) communities, particularly in remote settings.

Accurate diagnosis is essential as empirical antifungal treatment without examination leads to therapeutic failure in over 40% of cases where a non-candidal aetiology is present. A systematic approach incorporating history, clinical examination, and targeted investigations reduces unnecessary antimicrobial use and improves patient outcomes.

Pathophysiology & Aetiology

Genital itch results from stimulation of cutaneous C-fibres in the perigenital skin by inflammatory mediators, microorganisms, or mechanical irritation. The pathophysiology varies by aetiology:

Infective causes: Vulvovaginal candidiasis (Candida albicans 85–90%, non-albicans 10–15%), tinea cruris (Trichophyton rubrum, T. mentagrophytes), pubic lice (Phthirus pubis), scabies (Sarcoptes scabiei), HSV-1/2, molluscum contagiosum, bacterial vaginosis
Inflammatory/dermatological: Contact/irritant dermatitis, lichen sclerosus, lichen simplex chronicus, psoriasis, seborrhoeic dermatitis, atopic dermatitis, intertrigo
Systemic: Diabetes mellitus (promotes candidal overgrowth), iron deficiency, chronic renal failure, cholestasis, lymphoma
Neoplastic: Extramammary Paget disease, vulvar intraepithelial neoplasia (VIN), SCC in situ — must be excluded in persistent or refractory itch

Clinical Presentation & Diagnostic Criteria

Key features to elicit on history: onset and duration, character (constant vs nocturnal exacerbation), associated discharge, dysuria, sexual contacts, hygiene practices, topical product use, systemic symptoms. Physical examination of the genitalia, inguinal folds, perianal region, and skin beyond the genital area (feet, web spaces, trunk) is mandatory.

CANDIDIASIS

Vulvovaginal / Cutaneous

Intense itch, thick white "cottage cheese" discharge, erythema, satellite lesions, fissuring at introitus

Most common cause in women of reproductive age

TINEA CRURIS

Dermatophyte Infection

Annular scaly plaques with advancing border in inguinal folds; spares scrotum; associated tinea pedis common

More common in males; humid climates

LICHEN SCLEROSUS

Chronic Inflammatory Dermatosis

White atrophic "cigarette-paper" plaques, figure-of-eight perianal/vulvar distribution, purpura, architectural distortion

Post-menopausal women; uncircumcised men; risk of SCC

CONTACT DERMATITIS

Irritant / Allergic

Acute: erythema, vesicles, weeping. Chronic: lichenification, hyperpigmentation. Distribution mirrors exposure

Topical anaesthetics, fragrances, latex, lubricants

Investigations

Essential

High Vaginal Swab — Microscopy, Culture & Sensitivity

Clue cells, hyphae/pseudohyphae, trichomonads; Candida species and sensitivities; wet prep. Medicare item 69316. Speciate Candida if recurrent or treatment-resistant.
Essential

STI Screen — Chlamydia & Gonorrhoea NAAT

Endocervical/urethral or vulvovaginal swab. Medicare item 69384. Consider Mycoplasma genitalium NAAT in sexual health presentations.
Available

Skin Scrapings + KOH Microscopy

For tinea cruris — scrape advancing border; dermatophyte culture (2–4 weeks). Available at all Australian pathology labs.
Available

Blood Tests — Fasting Glucose / HbA1c

Exclude diabetes in recurrent candidiasis. FBC, iron studies if systemic cause suspected. HIV serology if indicated.
Specialist

Skin Biopsy

Required for suspected lichen sclerosus, lichen planus, psoriasis, VIN, or any persistent/atypical presentation unresponsive to initial therapy. Refer to dermatologist.
Specialist

Patch Testing

Refer to dermatologist if allergic contact dermatitis suspected. European standard series + genital series.

Risk Stratification

High-priority (urgent dermatology/gynaecology referral): Persistent itch >6 weeks unresponsive to treatment; ulceration, induration, or fixed lesions; pigmented or irregular lesions; suspected Paget disease or VIN
Moderate-priority (review 2–4 weeks): Suspected lichen sclerosus (biopsy confirmation required); recurrent candidiasis ≥4 episodes/year (Candida speciation + HbA1c needed); treatment-resistant tinea
Standard: First episode probable candidiasis with typical features; tinea cruris; contact dermatitis; pubic lice/scabies

Empirical Treatment by Aetiology

Vulvovaginal Candidiasis — First episode / mild-moderate:

💊

Clotrimazole 1% cream

Canesten® · Topical azole antifungal · First-line vulvar candidiasis

Adult DoseApply to affected area BD–TDS

PaediatricApply BD (nappy rash / candidal dermatitis)

RouteTopical

Duration7–14 days (vulvar cream); or 500 mg vaginal pessary single dose

Renal Adj.None required

Hepatic Adj.None required (topical, minimal systemic absorption)

PBS Status✓ PBS General Benefit

💊

Fluconazole 150 mg oral

Diflucan® · Systemic azole antifungal · Alternative to topical

Adult Dose150 mg single dose oral

PaediatricNot recommended <16 years for VVC

RouteOral

DurationSingle dose; repeat at 72h for severe infection

Renal Adj.Reduce dose if eGFR <50 mL/min for prolonged courses

Hepatic Adj.Use with caution in severe hepatic impairment

PBS Status✓ PBS General Benefit

⚠️

Pregnancy: Fluconazole oral is CONTRAINDICATED in pregnancy (teratogenic risk — cardiac defects). Use topical clotrimazole only throughout pregnancy.

Tinea Cruris:

💊

Terbinafine 1% cream

Lamisil® · Allylamine antifungal · First-line tinea cruris

Adult DoseApply once daily

PaediatricApply once daily (>12 years)

RouteTopical

Duration1–2 weeks

Renal Adj.None required (topical)

Hepatic Adj.None required (topical)

PBS Status✓ PBS General Benefit

Pubic Lice (Phthirus pubis):

💊

Permethrin 1% lotion

Lyclear® · Pyrethroid insecticide · First-line pubic lice

Adult DoseApply to affected area; leave 10 minutes; rinse thoroughly

PaediatricSafe ≥2 years; apply as per adult

RouteTopical

DurationSingle application; repeat at day 7–9 to kill newly hatched nymphs

Renal Adj.None required

Hepatic Adj.None required

PBS Status✓ PBS General Benefit

Scabies (Sarcoptes scabiei):

💊

Permethrin 5% cream

Lyclear Scabies® · Scabicide · First-line scabies

Adult DoseApply neck to toes including under fingernails; leave 8–12 hours; wash off

PaediatricInclude scalp and face in infants <2 years; avoid eyes/mouth

RouteTopical

DurationRepeat at day 7; treat all household contacts simultaneously

Renal Adj.None required

Hepatic Adj.None required

PBS Status✓ PBS General Benefit

Directed / Condition-Specific Therapy

Lichen Sclerosus (biopsy-confirmed):

💊

Clobetasol propionate 0.05% ointment

Dermol® · Potent topical corticosteroid · First-line lichen sclerosus

Adult DoseNightly × 4 weeks → alternate nights × 4 weeks → twice weekly maintenance

PaediatricAs per adult dosing; prepubertal LS may improve at puberty

RouteTopical

DurationLong-term twice-weekly maintenance to prevent relapse and reduce SCC risk

Renal Adj.None required (topical)

Hepatic Adj.None required (topical)

PBS Status⚠ PBS Authority Required

Recurrent VVC (≥4 episodes/year): Induction fluconazole 150 mg every 72h × 3 doses, then suppressive fluconazole 150 mg weekly × 6 months. Speciate Candida — non-albicans species (C. glabrata, C. krusei) require topical boric acid 600 mg pessary or specialist referral.

Contact Dermatitis: Remove causative agent. Bland emollient (Cetaphil, QV cream). Moderate-potency topical corticosteroid (hydrocortisone 1% mild; betamethasone valerate 0.02% moderate) × 2–4 weeks. Avoid soap, tight synthetic underwear, and fragranced products.

IV-to-Oral Switch Criteria

Genital itch presentations rarely require parenteral therapy. IV-to-oral switch is relevant in the uncommon scenario of severe disseminated candidiasis complicating immunosuppression. Switch from IV fluconazole to oral when: (1) clinical improvement evident; (2) tolerating oral intake; (3) no CNS, endophthalmitis, or endovascular involvement; (4) confirmed fluconazole-susceptible isolate on culture.

Monitoring Parameters

2 weeks

Candidiasis: Review if symptoms persist. Repeat high vaginal swab if no response. Check HbA1c in recurrent cases. Ensure partner treated if male balanitis coexists.

4 weeks

Tinea cruris: Review; check concurrent tinea pedis (reservoir). Culture if no response to confirm diagnosis and exclude non-dermatophyte mould.

3 months

Lichen sclerosus: Initial review at 3 months, then 6–12-monthly. Monitor for architectural changes, pigmented lesions, or induration suggesting VIN/SCC. Annual biopsy if suspicious changes.

4–6 weeks

Scabies: Post-scabetic itch may persist 4–6 weeks after successful treatment. Re-treat only if new burrows or living mites on dermoscopy. Consider crusted scabies if immunosuppressed.

Special Populations

🤰 Pregnancy

Candidiasis Topical clotrimazole preferred. Fluconazole oral CONTRAINDICATED (teratogenic risk). Use throughout pregnancy if symptomatic.

Scabies Permethrin 5% safe in 2nd/3rd trimester. Avoid 1st trimester if possible. Ivermectin contraindicated.

Pubic Lice Permethrin 1% safe. Avoid lindane (neurotoxic).

👶 Paediatrics

Lichen sclerosus Occurs in prepubertal girls. Clobetasol ointment effective. Spontaneous improvement at puberty in some. Must exclude sexual abuse.

Candidiasis (nappy rash) Satellite lesions diagnostic. Topical clotrimazole or miconazole. Address predisposing factors.

Scabies Apply permethrin including scalp and face in infants <2 years. Treat all household contacts simultaneously.

👴 Older Adults

Lichen sclerosus Predominant in post-menopausal women and older men. Co-prescribe topical oestrogen for vulvovaginal atrophy contributing to itch.

Drug-induced pruritus Opioids, statins, ACE inhibitors can cause genital itch. Comprehensive medication review essential.

🛡️ Immunocompromised

HIV / Transplant Increased risk of non-albicans Candida, crusted scabies, extensive tinea. Higher treatment failure rates. Lower threshold for specialist referral.

Crusted scabies Combination permethrin + ivermectin (200 mcg/kg days 1, 2, 8, 9, 15). Contact precautions. Notify public health.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples face a significantly higher burden of scabies and associated complications. In remote community settings, scabies prevalence may exceed 20% in children, with pyoderma, post-streptococcal glomerulonephritis, and acute rheumatic fever as recognised sequelae. Mass drug administration programs using oral ivermectin and topical permethrin have been implemented in the NT, Queensland, and WA under the Healthy Skin Program.

Geographic Remoteness

Access to dermatology and pathology limited in remote communities. Use telehealth dermatology services. Stockpile permethrin for Healthy Skin Program delivery.

Community Transmission

Household-level transmission requires simultaneous mass treatment. Coordinate with local ACCHO and NT/QLD/WA/SA health departments for Healthy Skin Program activation.

Cultural Safety

Engage Aboriginal Health Workers for contact tracing and health education. Provide translated resources. Ensure gender-concordant care where culturally required.

⚠️

Remote Community Protocol: For scabies in ATSI remote communities, follow state/territory Healthy Skin Program guidelines. Notify local ACCHO and public health unit. Mass treatment may be indicated.

Antibiotic Stewardship (ACSQHC NSQHS Standard 3)

Avoid empirical antifungal prescribing without clinical examination — at least 40% of patients self-diagnosing vaginal candidiasis have an alternative aetiology
Send appropriate microbiological specimens before prescribing antifungals in recurrent cases to guide speciation and susceptibility testing
Reserve oral fluconazole for cases where topical therapy is impractical or ineffective — topical agents preferred first-line to limit systemic azole exposure and drug interactions (CYP2C9/3A4)
Topical corticosteroids must be prescribed with clear instructions and follow-up — inappropriate potency or prolonged unsupervised use causes atrophy, striae, and secondary infection
Do not prescribe antibiotics for tinea cruris or candidiasis unless secondary bacterial superinfection is confirmed on culture

Follow-Up & Prevention

Candidiasis: Breathable cotton underwear; avoid tight clothing; minimise unnecessary antibiotic use; good glycaemic control in diabetes; probiotic supplementation (Lactobacillus rhamnosus GR-1/reuteri RC-14) as adjunct in recurrent VVC
Tinea cruris: Keep groin dry; antifungal powder (miconazole or clotrimazole) during humid months; treat tinea pedis concurrently; avoid sharing towels
Lichen sclerosus: Long-term follow-up mandatory — 4–6% lifetime risk of SCC. Annual review with biopsy of suspicious lesions. Educate patient on vulvar/penile self-examination.
Contact dermatitis: Permanently avoid causative allergen/irritant. Use soap-free cleansers and emollients for skin barrier maintenance.
Pubic lice & scabies: Partner notification and treatment. Full STI screen for co-existent STIs. Safer sex counselling. Online notification: letthemknow.org.au

References

01
Fischer G. Chronic vulvar dermatoses. Australas J Dermatol. 2010;51(1):1–9.
02
Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961–1971.
03
Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by IDSA. Clin Infect Dis. 2016;62(4):e1–e50.
04
Australasian College of Dermatologists. Lichen Sclerosus Clinical Practice Guideline. Sydney: ACD; 2019.
05
Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.
06
Andrews RM, McCarthy J, Carapetis JR, Currie BJ. Skin disorders, including pyoderma, scabies, and tinea infections. Pediatr Clin North Am. 2009;56(6):1421–1440.
07
Northern Territory Department of Health. Healthy Skin Program: Guidelines for the Control of Scabies and Tinea in Remote Communities. Darwin: NT DoH; 2020.
08
Gunning K, Pippitt K, Kiraly B, Sayler M. Pediculosis and scabies: treatment update. Am Fam Physician. 2012;86(6):535–541.
09
Royal Australian College of General Practitioners. Guidelines for Preventive Activities in General Practice (Red Book). 9th ed. Melbourne: RACGP; 2016.
10
Oakley A. Genital itch. DermNet New Zealand. Updated 2023. Available from: https://dermnetnz.org/topics/genital-itch
11
Bohl TG. Overview of vulvar pruritus through the life cycle. Clin Obstet Gynecol. 2015;58(3):464–473.
12
Pharmaceutical Benefits Scheme. PBS Online. Canberra: Australian Government Department of Health; 2024. Available from: https://www.pbs.gov.au